Akari Therapeutics Plc: CEO Gaslightwala Abizer exercised 27,066 shares

What happened

• The filing says Gaslightwala Abizer, CEO and director, exercised and converted pre-funded warrants into 19,333 ADSs and 7,733 ADSs (total 27,066 ADSs) and sold those ADSs on Oct 14, 2026 at $16.16 per ADS for $312,421 and $124,965, respectively (total $437,386).
• The filing also reports that on Aug 18, 2026 Abizer was granted an option to purchase 174,000 ADSs (derivative), recorded at $0 in the filing and subject to vesting and shareholder approval conditions (see footnote).

Key details

• Transaction dates and prices:
  • Oct 14, 2026: exercised/converted pre-funded warrants yielding 19,333 ADSs (acquired at $0; reported value $8) and 7,733 ADSs (acquired at $0; reported value $3); those ADSs were disposed at $16.16 per ADS for $312,421 and $124,965, respectively.
  • Aug 18, 2026: grant of option to purchase 174,000 ADSs at $0 (derivative).
• Shares owned after the transaction: not stated in the information provided.
• Relevant footnotes from the filing:
  • The Aug 18, 2026 option grant (174,000 ADSs) is subject to forfeiture if shareholder approval to increase the equity plan is not obtained; vesting accrues from Mar 18, 2026 at 2.08% per month after shareholder approval, with the remainder vesting monthly until the four-year anniversary of Mar 18, 2026, subject to continued service (F1).
  • Shareholder approval that made the pre-funded warrants exercisable was obtained on Mar 2, 2026 (F2); the pre-funded warrants remain exercisable until fully exercised (F3).
  • The 19,333 ADS-related pre-funded warrants originated from a Dec 16, 2025 note exchange; the 7,733 ADS-related pre-funded warrants originated from a Dec 16, 2025 private placement; combined purchase price per pre-funded warrant and accompanying warrant was $16.16 (F4–F6).
• Whether it was filed late: not indicated in the information provided.

Why it may matter

• The filing says the exercised pre-funded warrants were sold on the same date as exercise (the ADSs were disposed on Oct 14, 2026), i.e., the exercised shares were sold at the time of exercise.
• The Aug 18, 2026 entry is a derivative option grant subject to shareholder approval and vesting terms rather than an immediate market purchase.
• This filing does not show why the insider traded or why the company acted.